Complex ABO Glycan Phenotypes Predicted by Lectin Microarrays
|
By LabMedica International staff writers Posted on 16 Sep 2020 |

Image: The LecChip and GlycoStation were used to identify subtle surface ABO blood group glycoprotein density variations (Photo courtesy of Glycotechnica).
Serological classification of individuals as A, B, O, or AB is a mainstay of blood banking. ABO blood groups or ABH antigens, in addition to other surface glycans, act as unique red blood cell (RBC) signatures and direct immune responses. ABO subgroups present as weakened, mixed field, or unexpected reactivity with serological reagents, but specific designations remain complex.
Lectins detect glycan motifs with some recognizing ABH antigens. Adaption of high-throughput microarrays spotted with a multitude of lectins, including lectins that recognize blood groups, may complement current methods for a more thorough interpretation of RBC ABH expression. Although many lectins have the ability to bind unique blood group antigens, few are tested for ABO-specific agglutination and, thus, limit their use in transfusion medicine.
Medical scientists at the Medical College of Wisconsin (Milwaukee, WI, USA) evaluated a 45-probe lectin microarray to rapidly analyze ABO blood groups and associated unique glycan signatures within complex biological samples on RBC surface glycoproteins. RBC membrane glycoproteins were prepared from donor RBCs, using 20 samples for each blood group. ABO blood group was distinguishable by lectin array, including variations in ABH antigen expression not observed with serology.
The total protein content from each extracted cell fraction was determined using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The LecChip (Glycotechnica, Yokohama, Japan) was chosen as a testing platform because it provided a wide selection of lectins compared with other commercially available microarrays. Fluorescent microarray images were acquired using the Glycotechnica evanescent-field fluorescence scanner, GlycoStation Reader 2200. Samples were applied in a grid format to the membrane PVDF membranes for immunoblotting.
The team used principal component analysis and highlighted broad ABO blood group clusters with unexpected high and low antigen expression and variations were confirmed with ABH antibody immunoblotting. Using a subset of lectins provided an accurate method to predict an ABO serological phenotype. Lectin microarray highlighted the importance of ABO localization on glycoproteins and glycolipids and pointed to increased glycocalyx complexity associated with the expression of A and B antigens including high mannose and branched polylactosamine. Thus, lectins identified subtle surface ABO blood group glycoprotein density variations not detected by routine serological methods.
The authors concluded that their study showed that ABH antigens on RBC glycoproteins were distinguishable by lectin array. Their analysis was limited to interrogating glycoproteins, but highlighted the importance of ABH localization on glycoproteins even within the same blood group. They identified changes associated with the expression of A and B antigens with increased levels of terminal and high mannose and branching polylactosamine. The study was published on August 21, 2020 in the journal Blood Advances.
Related Links:
Medical College of Wisconsin
Thermo Fisher Scientific
Glycotechnica
Lectins detect glycan motifs with some recognizing ABH antigens. Adaption of high-throughput microarrays spotted with a multitude of lectins, including lectins that recognize blood groups, may complement current methods for a more thorough interpretation of RBC ABH expression. Although many lectins have the ability to bind unique blood group antigens, few are tested for ABO-specific agglutination and, thus, limit their use in transfusion medicine.
Medical scientists at the Medical College of Wisconsin (Milwaukee, WI, USA) evaluated a 45-probe lectin microarray to rapidly analyze ABO blood groups and associated unique glycan signatures within complex biological samples on RBC surface glycoproteins. RBC membrane glycoproteins were prepared from donor RBCs, using 20 samples for each blood group. ABO blood group was distinguishable by lectin array, including variations in ABH antigen expression not observed with serology.
The total protein content from each extracted cell fraction was determined using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The LecChip (Glycotechnica, Yokohama, Japan) was chosen as a testing platform because it provided a wide selection of lectins compared with other commercially available microarrays. Fluorescent microarray images were acquired using the Glycotechnica evanescent-field fluorescence scanner, GlycoStation Reader 2200. Samples were applied in a grid format to the membrane PVDF membranes for immunoblotting.
The team used principal component analysis and highlighted broad ABO blood group clusters with unexpected high and low antigen expression and variations were confirmed with ABH antibody immunoblotting. Using a subset of lectins provided an accurate method to predict an ABO serological phenotype. Lectin microarray highlighted the importance of ABO localization on glycoproteins and glycolipids and pointed to increased glycocalyx complexity associated with the expression of A and B antigens including high mannose and branched polylactosamine. Thus, lectins identified subtle surface ABO blood group glycoprotein density variations not detected by routine serological methods.
The authors concluded that their study showed that ABH antigens on RBC glycoproteins were distinguishable by lectin array. Their analysis was limited to interrogating glycoproteins, but highlighted the importance of ABH localization on glycoproteins even within the same blood group. They identified changes associated with the expression of A and B antigens with increased levels of terminal and high mannose and branching polylactosamine. The study was published on August 21, 2020 in the journal Blood Advances.
Related Links:
Medical College of Wisconsin
Thermo Fisher Scientific
Glycotechnica
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Blood Test Could Detect Infection Exposure History
Every infection leaves a lasting imprint on the immune system, but current diagnostic tools can usually detect exposure to only one pathogen at a time. This makes it difficult to understand a person’s... Read more
Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
Malaria remains the deadliest parasitic disease worldwide, and although it is not endemic in countries such as Spain, imported cases are diagnosed every year in travelers returning from high-risk regions.... Read more
Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Monitoring minimal residual disease (MRD) after bladder cancer treatment is critical because early relapse often occurs before tumors are visible by imaging or cystoscopy. Urine tumor DNA analysis offers... Read more
Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
Primary central nervous system lymphoma (PCNSL) is typically diagnosed through surgical biopsy, which remains the gold standard but carries substantial risk. Operability depends heavily on tumor location,... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more
Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read moreTechnology
view channel
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







